<DOC>
	<DOC>NCT01432535</DOC>
	<brief_summary>This study will compare the pharmacokinetics of a single dose of peginterferon alfa-2b (Sylatron®) in healthy participants to that in participants with moderate to severe impairment of kidney function.</brief_summary>
	<brief_title>Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Body Mass Index (BMI) between 19 to 40 kg/m^2, inclusive Moderate renal impairment and severe renal impairment and/or endstage renal disease (ESRD) who may require hemodialysis and normal renal function Free of any clinically significant disease (except those related to renal disease and comorbid conditions) that requires a physician's care and would interfere with the study Females of reproductive potential must have used a medically accepted method of contraception for three months prior to screening and must agree to use an accepted contraceptive method during and for two months following the study Males must agree to use a medically accepted method of contraception during the trial and for 3 months after the study Pregnant, intend to become pregnant, or breastfeeding Surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug History of any infectious disease within 4 weeks prior to study drug administration that affects ability to participate in the study Positive for hepatitis B surface antigen, and/or for human immunodeficiency virus (HIV) antibodies. Healthy participants positive for hepatitis C antibodies Previously received PegIntron®, Sylatron®, and/or Pegasys More than 10 cigarettes or equivalent tobacco use per day History of malignancy Hypothyroidism or hyperthyroidism History of depression requiring treatment with psychotherapy or medication History of suicidality or at risk of selfharm or harm to others History of autoimmune disorder requiring medical therapy Immune mediated renal insufficiency Removal of a kidney (healthy participants) or functioning renal transplant (participants with renal impairment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>